Stellaromics

Stellaromics Inc, founded in 2022 and headquartered in Boston, is advancing biomedical research with its patented technology capable of deciphering complex 3D transcription and translation patterns in native biological tissues. Their flagship product, STARmap (Spatially-resolved Transcriptomic Amplified Reads Mapping), reveals gene expression patterns within intact tissues, aiding in the identification of therapeutic targets and supporting biomedical research. Stellaromics' Plexa™ series is in the late stages of product development, designed to enable researchers and clinicians to create detailed cellular maps to enhance disease understanding.